Non-metals and compounds thereof (A61K47/04)

Pharmaceutical composition // 2642624
FIELD: pharmacology.SUBSTANCE: version 1 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg or ciclesonide in an amount of 20-800 μg, lactose and optionally one or more pharmaceutically acceptable excipients. Version 2 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg and tiotropium in an amount of 2.25-30 μg, lactose and optionally one or more pharmaceutically acceptable excipients. The composition is in a form suitable for administration once a day.EFFECT: composition according to the invention simplifies the mode of drug administration in the treatment of respiratory, inflammatory or obstructive airway diseases.2 cl, 49 ex

Biodegradable devices based on silicon for therapeutic agents delivery // 2640918
FIELD: medicine.SUBSTANCE: biodegradable devices are described, such as implants for the controlled delivery of therapeutic agents, in particular large molecules such as proteins and antibodies. The devices contain a porous silicon carrier material impregnated with a therapeutic agent. An improved dosage form for controlled release of therapeutic agents can be used in vitro or in vivo to deliver the therapeutic agent during an estimated period of time, for example, several days, weeks or months.EFFECT: device can be used to treat or prevent the patient's conditions, such as chronic diseases.19 cl, 3 dwg, 6 tbl, 6 ex

Pharmaceutical composition containing biotin and method for its production // 2639488
FIELD: pharmacology.SUBSTANCE: group of inventions refers to pharmaceutical compositions for polyneuropathy prevention and treatment as a solid dosage form with extended release, comprising Biotin - 40-60 wt % as an active agent, as well as Methocel K100 LV - 14-21 wt %, Methocel K4M - 5-10 wt %, microcrystalline cellulose (MCC) - 7-18 wt %, copovidone - 1.5-3 wt %, colloidal silicon dioxide - 0.4-1 wt % and a pharmaceutically acceptable stearic acid salt - 0.6-1 wt %, as well as to a method for its production, according to which Biotin, Methocel K4M, Methocel K100 LV, MCC and copovidone are sieved and mixed until homogeneous, stearic acid salt, colloidal silicon dioxide are mixed, the mixture is compacted by rolling, colloidal silicon dioxide is added and mixed together with pre-compacted grains, followed by addition of stearic acid salt, stirring and formation a solid dosage form.EFFECT: creation of a new medicinal composition with high technological properties, high stability and reproducible kinetics of active agent release.9 cl, 8 ex, 5 tbl, 1 dwg
ethod for cardioplegia // 2635523
FIELD: medicine.SUBSTANCE: to stop the heart and maintain it in a stopped state, a cardioplegic solution is used which is obtained from the following components: potassium chloride - 7.45 g; magnesium sulfate - 2.34 g; trometamol - 0.5 g; mannitol - 35.9 g; distilled water - up to 1000 ml, with introduction of 1 M hydrochloric acid until a pH of 7.6-8.0, which is mixed with blood from the oxygenator in a ratio of 1:1 to 1:4 and injected into the heart at a rate of 100-300 ml/min using at least 400 ml of solution; and to maintain the asystole, a cardioplegic solution is used which is obtained from the following components: potassium chloride - 2.125 g; magnesium sulfate - 2.34 g; trometamol - 0.5 g; mannitol - 58.28 g; distilled water - up to 1000 ml, with introduction of 1 M hydrochloric acid until a pH of 7.6-8.0, which is mixed with blood from the oxygenator in a ratio of 1:4 and injected into the heart at a rate of 100-150 ml/min.EFFECT: improved safety of cardioplegia using different cardioplegic solutions.3 ex

Compositions with controlled release and methods of their use // 2627429
FIELD: veterinary medicine.SUBSTANCE: composition contains the therapeutically effective amount of at least one active substance and the base, containing colloidal silicon dioxide in the concentration from 0.1 upto 5% by weight, at least one oil and at least one surface active agent in the concentration from 0.01 upto 10% by weight. The active agent is chosen from the group of antibiotics, containing betalactams, penicillins, cephalosporins, aminoglycosides, quinolones, sulfonamides, tetracyclines, macrolides and combinations thereof. The oil is selected from the group, consisting of triglycerides, light vaseline oil, ethyl oleate, sesame oil and peanut oil. The colloidal silicon dioxide is dispersed in the oil in the composition according to the invention. The viscosity of the composition is less than 1000 mPas at the shear rate of 100 1/s and at the temperature of 20°C. Also described the composition manufacturing method and application for treating or preventing measures of mastitis at the animal which need it.EFFECT: according to the invention the composition provides the controlled release of the active agents from the composition with low viscosity.24 cl, 16 dwg, ex 18
Pharmaceutical preparation for rheumatological diseases treatment // 2627424
FIELD: pharmacology.SUBSTANCE: pharmaceutical preparation in the form of a solution for use in rheumatological diseases treatment contains a combination comprising sodium diclofenac or naproxen sodium, betamethasone sodium phosphate and hydroxy-cobalamin sulfate as active substances and benzyl alcohol, propylene glycol, sodium metabisulphite and water for injection as auxiliary components. A method for production of the preparation is described as well.EFFECT: stable, effective formulation with analgesic, anti-inflammatory and antineurotic effects.4 cl, 1 tbl, 4 ex

Pharmaceutical composition for histone deacetylase inhibitors // 2625758
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for topical application is shown. It comprises of a therapeutically effective amount of active pharmaceutical ingredient (API) - a compound of the structural formula of at least one acidifying agent and a base carrier comprising of at least one pharmaceutically acceptable nonaqueous solvent. The acidifying agent is separated from citric acid, acetic acid and phosphoric acid. The measured pH value of the pharmaceutical composition is from 3 to 5. Preferably, the pharmaceutically acceptable nonaqueous solvent is a mixture of ethanol and propylene glycol. Also, a kit for preparing a pharmaceutical composition and a method for treating a proliferative, immune and skin diseases in a subject are desribed. The values of n, R1 and R2 in the structural formula (I) are defined in the claims.EFFECT: stabilized pharmaceutical composition is obtained.26 cl, 1 dwg, 18 tbl, 3 ex
Clozapine tablets with delayed release and method of obtaining thereof // 2624229
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to field of chemical-pharmaceutical industry, namely to pharmaceutical composition in form of tableted form with delayed release, which contains 30-40 wt % of clozapine as active component and additional substances: 20-35 wt % of Methocel K100 LV, 10-15 wt % of Methocel K4M, 12-30 wt % of microcrystalline cellulose, 2-3 wt % of copovidone, 0.5-1 wt % of colloidal silicon dioxide and 0.5-1 wt % of pharmaceutically acceptable salt of stearic acid, as well as to method of obtaining said pharmaceutical composition.EFFECT: group of the inventions provides obtaining clozapine tablets, possessing stability and reproducible kinetics of delayed release of active substance.8 cl, 4 ex, 4 tbl, 3 dwg

Tablets of clozapine with sustained release // 2613192
FIELD: pharmacy.SUBSTANCE: group of inventions relates to a pharmaceutical formulation of clozapine with sustained release in the form of tablets, film coated, containing 30.0-50.0 wt % of clozapine, 20.0-30.0 wt % of microcrystalline cellulose, 4.0-6.0 wt % of lactose monohydrate, 15.0-25.0 wt % of hydroxypropyl methylcellulose HPMC K15M, 1.0-3.0 wt % of hydroxypropyl methylcellulose HPMC 2910, 1.0-3.0 wt % of colloidal silicon dioxide, 0.05-1.5 wt % of pharmaceutically acceptable salts of stearic acid and 2.0-4.0 wt % of film coating which comprises polyvinyl alcohol, titanium dioxide, macrogol and acceptable dyes or a mixture Opadry II yellow; as well as to a process for preparing such a pharmaceutical composition.EFFECT: obtaining a stable pharmaceutical composition of clozapine in the form of tablets with sustained release and stable technological properties, as well as reproducible release kinetics of the active substance.9 cl, 5 ex, 1 tbl, 2 dwg
Agent for treating and preventing disorders of autism spectrum // 2608444
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to psychopharmacology, and concerns an agent for treating and preventing disorders of autism spectrum, representing glycine, immobilized on detonation nano-diamond particles size of 2–10 nm, with content of glycine from 1 to 21±3 wt%.EFFECT: claimed device allows improving effectiveness of medical treatment and prevention of autism and expand the range of effective and safe psychotropic agents.1 cl, 5 tbl, 2 ex

Agent having antioxidant, anti-tumor, immunomodulatory, anti-diabetic and anti-bacterial action // 2598349
FIELD: medicine.SUBSTANCE: proposed agent having antioxidant, anti-tumor, immunomodulatory, anti-diabetic and anti-bacterial action, relates to medicine. It comprises an aqueous extract from plant material. As a raw material use peach and birch leaves. In addition, agent contains ascorbic acid and the trivalent chromium microelement in the amounts indicated in the invention formula.EFFECT: agent of the invention expands the range of drugs, has no adverse side effects and can be recommended for long-term continuous use.1 cl, 1 dwg, 4 tbl

ethod and composition // 2571566
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics. What is described is an aqueous pharmaceutical solution containing 2-(hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one or its pharmaceutically acceptable salt and pH-controlling agent. The above agent is specified in pharmaceutically acceptable organic or inorganic acids, pharmaceutically acceptable acid buffers or any mixture thereof. What is also described is using the above aqueous pharmaceutical solution for producing a drug for treating a disease specified in hyperproliferative diseases, autoimmune diseases and cardiac diseases.EFFECT: group of inventions provides better shelf-life and reduced degradation rate of the above active compound.19 cl, 9 tbl, 2 dwg, 7 ex

System for delivering biologically active substances into organism and method of obtaining thereof // 2560697
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the pharmaceutical industry, namely to a system for delivering biologically active substances into an organism. The system for delivering biologically active substances into the organism represents a nanodiamond with the particle size of 2-10 nm, the surface of which is modified with chlorine with the chlorine content up to 14 atomic%. A method of obtaining the system for delivering biologically active substances into the organism, representing the nanodiamond with the particle size of 2-10 nm, the surface of which is modified with chlorine with the chlorine content to 14 atomic% consists in the fact that annealing of the nanodiamond particles is carried out at a temperature of 500-1200°C in the flow of gaseous hydrogen with the further liquid-phase chlorination of the obtained particles with molecular chlorine, dissolved in carbon tetrachloride under a photochemical impact of visible light and heating, after which the suspension is centrifuged, washed and dried under specified conditions.EFFECT: said method makes it possible to obtain the system for delivering biologically active substances into the organism, representing nanodiamond particles, which do not contain fluorine, capable of effective binding of various biologically active and medicinal substances.8 cl, 13 dwg, 3 tbl, 11 ex
Hypotensive means // 2554815
FIELD: medicine.SUBSTANCE: invention represents a hypotensive means, which contains felodipinum as an active component, as well as target additional components: mesoporous silicon dioxide, lactose, hypromeloza. Realisation of the invention ensures the high technological efficiency of the claimed medical means production with the provision of a prolonged release of an active substance with the application of available components. Felodipinum is included into spherical particles with a highly developed mesoporous structure of silicon oxide.EFFECT: increase of stability in storage and protection from unfavorable environmental factors.4 cl, 4 ex
Pharmaceutical composition in form of tablet and method of obtaining thereof // 2546002
FIELD: medicine.SUBSTANCE: composition includes glutaryl histamine in an amount of 18.0-75.0 wt % as an active substance, and as auxiliary substances: microcrystalline cellulose in an amount of 18.0-71.0 wt %, sodium croscarmellose in an amount of 0.25-1.0 wt %, colloidal silicon dioxide in an amount of 0.5-2.0 wt %, calcium stearate in an amount of 0.5-2.0 wt % and lactose monohydrate. The invention also relates to a method of obtaining the said composition.EFFECT: invention is characterised by the high bioavailability of the active component and high pharmacological activity.4 cl, 6 tbl, 3 ex
Dosage form of clopidogrel // 2540519
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a dosage form of Clopidogrel presented in the form of a solid gelatine capsule. The dosage form contains Clopidogrel hydrogen sulphate, lactose anhydride, microcrystalline cellulose, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate.EFFECT: according to the invention, the dosage form of Clopidogrel contains a high amount of the active ingredient; it is prepared without the use of a wet granulation technique, and provides the more accurate dosage of the ingredients and the stability of the substances used.9 tbl
Pharmaceutical composition for treating eye diseases related to eye tissue metabolic disease and inflammatory eye tissue injury // 2521337
FIELD: medicine.SUBSTANCE: pharmaceutical composition can additionally contain ethylenediaminotetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, a preserving agent specified in a group: Nipagin, Nipasol, benzoic acid, sodium benzoate, sorbic acid, benzalkonium chloride. As a body-forming base, the composition can contain distilled water, polyethylene oxide 400, polyethylene oxide 4000, polyethylene glycol, propylene glycol, a phosphate buffer, a borate buffer, an acetate-borate buffer depending on a dosage form.EFFECT: high therapeutic effectiveness, prolonged corneal contact of the preparation which reduces the number of instillations, avoids a risk of side effects and provides good tolerance.5 cl, 5 ex
Drug preparation for treating cardiac arrhythmia // 2513580
FIELD: medicine.SUBSTANCE: drug preparation represents a composition containing: lappaconitine hydrobromide 0.02 - 0.06 g, pregelatinised starch 0.0335 - 0.0536 g, lactose monohydrate 0.058 - 0.122 g, hypromellose 0.078 - 0.161 g, calcium stearate 0.002 - 0.004 g and colloidal silicone dioxide 0.002 - 0.004 g.EFFECT: prolonged antiarrhythmic action of the active ingredient lappaconitine hydrobromide with accessory alkaloids.5 cl, 1 tbl

ethod for selective final purification of nanodiamond // 2506095
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to pharmacology, nanomaterials and nanotechnology, and concerns a method for selective final purification of nanodiamonds to remove foreign nitrate ions and sulphur compounds to be used in pharmaceutics; the method implies that charge-free nanodiamond powder is treated with alkaline water of the concentration of 0.01-1 mole/l at 20-100°C; the prepared suspension is then decanted and centrifuged; the precipitation is washed with water using ultrasound, separated and dried.EFFECT: higher effectiveness of the method.5 cl, 1 dwg, 7 ex
Eye drops // 2504372
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to eye drops that contain 1-3 wt % of taurine, 0.01-0.1 wt % of dexamethasone, 0.4-0.6 wt % of boric acid, 0.4-0.6 wt % of hydroxypropyl methyl cellulose and water. The eye drops aim at treating various eye diseases related to metabolic disturbance in eye tissues, and inflammatory injury of an eye surface.EFFECT: higher therapeutic efficacy of the eye drops.3 ex

New controlled-release active agent carrier // 2502506
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to a controlled-release active agent carrier. The declared carrier contains a natural or synthetic calcium carbonate with an activated surface whereto an active agent is bound. Natural or synthetic calcium carbonate with the activated surface represents a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one acids wherein carbon dioxide is formed in situ when processed by an acid and or supplied from an external source.EFFECT: invention also refers to a method for preparing the controlled-release carrier which consists in providing calcium carbonate with the activated surface in the form of a tablet or a powder, providing the active agent in the form of a solution or a suspension, contacting calcium carbonate with the activated surface with the active agent and separating the carrier from excess fluid.17 cl, 5 dwg, 4 ex

Fine granules having improved characteristics in water suspension // 2488396
FIELD: medicine, pharmaceutics.SUBSTANCE: there are described fine granules containing cefcapene pivoxil hydrochloride wherein cefcapene pivoxil hydrochloride particles are coated with a hydrophobic substance, preferentially hydrogenated oil. The fine granules also contain silicone dioxide and a surfactant having a melting point 30°C or more. Preferentially, as a surfactant, the fine granules contain polyoxyethylene(160)polyoxypropylene(30)glycol.EFFECT: invention provides improved water affinity of the fine granules, and the improved characteristics of the water suspension of the fine granules of cefcapene pivoxil hydrochloride.14 cl, 5 dwg, 8 tbl, 9 ex
Combined antihypertensive drug and method for preparing it // 2483728
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a combined antihypertensive drug containing an agent presented by Amlodipine besilate and Lisinopril dehydrate mixed with an excipient. As the excipient, the specified antihypertensive drug contains microcrystalline cellulose of an average particle size of 90-100 mcm and a bulk density of 0.28-0.33 g/ml; as additives, it contains colloidal silicon dioxide, magnesium stearate and sodium carboxymethyl starch. The invention also refers to a method for preparing the mentioned antihypertensive drug by direct compression.EFFECT: providing a stable drug preparation, more storage-stable, having high producibility, active substance distribution uniformity and bioavailability.8 cl, 2 tbl, 3 ex
Pharmaceutical antidiabetic composition and method of obtaining antidiabetic composition // 2482846
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of medicine, namely, to antidiabetic composition. Method of obtaining antidiabetic pharmaceutical composition includes preparation of trituracio mixture of active substance repaglinide, taken in therapeutically efficient quantity, with complex-forming substance, solubiliser and colloid silicon dioxide, further addition of filling agent, disintegrant and lubricant, and tabletting by method of direct pressing.EFFECT: pharmaceutical composition in form of tablet, obtained by claimed method, is characterised by high degree of active substance release, satisfactory strength and has storage term longer than 2 years.10 cl, 1 tbl
ethod for preparing drug and biologically active preparations // 2479318
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely a method for preparing a drug or biologically active preparation. The declared method involves dissolving sodium bicarbonate and potassium bicarbonate in water so that the ratio of sodium to potassium ions in water is 2-6:1. Then a redox potential of the prepared solution is reduced to the value of 0 mV to -900 mV, and the active ingredient of the drug or biologically active preparation is dissolved the prepared solution.EFFECT: preparing the drug or biologically active preparations the active ingredient of which is found in the time-stable reduced form.2 cl, 2 tbl, 12 ex

Prolonged release drug preparation, adsorbent, functional foodstuff, mask and adsorbent layer // 2476230
FIELD: medicine, pharmaceutics.SUBSTANCE: declared group of inventions which refers to an adsorbent, a mask with adsorbent and an absorbent layer for organic substance adsorption, an adsorbent for allergen adsorption, an adsorbent to be used in medicine and an oral adsorbent. Said adsorbents, mask and adsorbent layer contains a porous carbon material comprising spherical pores having average diameter of 1×10-9 to 1×10-5 and regularly spaced (in an orderly fashion) with a surface area of the material making more than 3x102 m2/g.EFFECT: invention provides preparing the adsorbents with high adsorbent ability.37 cl, 4 dwg, 20 tbl, 7 ex
Pharmaceutical composition for preparing infusion solutions of antimicrobial preparations, method for preparing it (versions) // 2476206
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutical compositions for preparing infusion solutions of antibacterial and antimycotic preparations, and to methods for preparing them. The declared pharmaceutical compositions are presented in the form of powder, contain sodium chloride and dextrose and particles of colloidal silicone dioxide among which a portion of particles of 5 mcm and less makes less than 35%, in certain weight proportions. A method for preparing said pharmaceutical compositions consists in the fact that sodium chloride in the form of powder and dextrose in the form of powder are mixed with powdered colloidal silicone dioxide in certain proportions; the prepared mixture is mechanically treated by impact abrasion to increase a weight portion of fine particles of silicone dioxide of 5 mcm or less to min. 35%.EFFECT: group of inventions provides the intensified therapeutic effectiveness of parenteral forms of the antibacterial and antimycotic preparations.4 cl, 4 tbl, 3 ex
ethod for preparing composition for injections containing sodium cevtriaxone and sodium tazobactam // 2471484
FIELD: medicine, pharmaceutics.SUBSTANCE: method for preparing a composition for injections containing sodium cevtriaxone and sodium tazobactam involves the following stages: (a) suspension of raw materials, i.e. sodium cevtriaxone, sodium tazobactam, sterilised water for injections, mixed solution of ethyl acetate and isopropyl alcohol, and anhydrous ethanol in mass relation making 3-5:1:2:5:9, with volume relation of ethyl acetate to isopropyl alcohol making 1:2-4; (b) dissolution of sodium cevtriaxone and sodium tazobactam in sterilised water for injections with added activated hydrocarbon and filtration; (c) addition of the mixed solution of ethyl acetate and isopropyl alcohol to the filtrate and agitation of the mixture; addition of a seed crystal of sodium cevtriaxone to the solution for crystallisation initiation; and finally washing of the crystals in anhydrous ethanol and crystal drying; and (d) lyophilisation to form the composition for injections containing sodium cevtriaxone and sodium tazobactam.EFFECT: composition is characterised by high uniformity, high degree of purity and safety of use.6 cl, 2 tbl, 3 ex

Corticosteroid-based composition with controlled release for treatment of ear diseases // 2469726
FIELD: medicine.SUBSTANCE: pharmaceutical composition, suitable for application in treatment of ear diseases includes acceptable for ear thermoreversable water gel. Pharmaceutical composition consists of anti-inflammatory corticosteroid in form of multiple particles and polyoxypropylene and polyoxyethylene-based polymer. Composition is introduced locally to the subject, suffering from ear disease, by intratympanic introduction on membrane of cochlea window or near it.EFFECT: composition in accordance with invention ensures prolonged release of anti-inflammatory corticosteroid through membrane of cochlea window into inner ear cochlea during, at least, 5 days after a single introduction.12 cl, 9 dwg, 9 tbl, 31 ex

ethod of obtaining iron-carbon nanoparticles // 2465008
FIELD: chemistry.SUBSTANCE: invention relates to a method of obtaining iron-carbon nanoparticles, characterised by that iron granules are treated with pulsed electric discharges in a reactor in octane or decane dispersion medium. Treatment is carried out with pulse energy of 0.5-1 J, voltage of 500 V, pulse frequency of 400 Hz, pulse duration of 15 mcm, discharge current of 250 A, and time for exposure to pulsed electric discharges is selected in the 50-120 s interval. The solid phase is separated from the obtained suspension by separate removal from the reactor of a suspension with a coarse fraction with particle size greater than 0.5-1.5 mcm and a suspension with a fine fraction with particle size 57-65 nm, from which a magnetic fraction is separated and then dried and heated to 150°C.EFFECT: invention increases size homogeneity (particle size 57-70 nm), magnetic susceptibility and specific surface area of iron-carbon nanoparticles.2 tbl, 1 dwg
Granule and method for making thereof // 2456980
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.EFFECT: granules possess fast disintegration, contain a small amount of the carrier and contain a low single dose.12 cl, 5 ex

Preparation containing biologically active substances // 2448684
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a biologically active preparation which contains active substances in a liquid phase in an effective amount. Said preparation represents a disperse system with a liquid disperse phase in a microdrop state stabilised by a dry high-disperse inert hydrophobic disconnector which is silicone dioxide with nano-sized particles. The amount of the liquid disperse phase makes 62-91 wt %, while the amount of the disconnector makes 9-38 wt %.EFFECT: higher dispersion of the preparation, higher efficacy and bioavailability and GIT protection.4 cl, 1 tbl, 2 dwg, 13 ex
ethod of sublimation dehydration of high-disperse biologically active materials // 2440106
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents a method of sublimation dehydration of high-disperse biologically active materials found in a microdrop state characterised by the fact that the microdrop powder is frozen at temperature -35°C to -45°C for 1.5 to 8 h, and then dehydrated.EFFECT: invention provides reduced duration of the dehydration process of biologically active materials.3 ex

Process for producing fine-grained biologically active materials // 2440105
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and represents a method for producing fine-grained biologically active materials containing active substances, characterised by the fact that the liquid with biologically active substances is dispersed to the microdrop state in a layer of dry fine-grained inert hydrophobic aerosil in the proportion 10:1.5 to 10:6, to form thereby liquid microdrops surrounded by hydrophobic aerosil particles and powdered which, if necessary, are dried by a technologically acceptable method.EFFECT: invention provides increasing dispersion of biologically active materials.11 ex, 2 dwg
ethod of combination dehydratation of high-disperse biologically active materials // 2440099
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents a method of combination dehydratation of high-disperse biologically active materials containing active substances in a liquid phase, implemented in stages and differing by the fact that the liquid phase with the active substance in a microdrop state stabilised by a dry high-disperse hydrophobic disconnector in ratio 1:3-1:22, is dehydrated initially at atmospheric pressure and then by mixing with a high-absorbency sorbent with residual moisture less than 1% and dried up if needed.EFFECT: invention provides higher activity of the active substances.9 ex, 1 tbl
Preparation containing biologically active substances // 2440098
FIELD: medicine.SUBSTANCE: invention refers to pharmaceutical industry and represents a preparation containing a biologically active substance, characterised by the fact that it contains a powder based on dried microdrops of the active substance stabilised by a dry high-disperse inert hydrophobic disconnector representing silicone dioxide with the components of the preparation being in the certain mass ratio per 1 g of the preparation.EFFECT: invention provides higher dispersity of the preparation and preservation of the active substances in the preparation.13 ex, 2 tbl

ethod of targeted transport of biologically active substances and application of stem cells for targeted transport // 2426785
FIELD: medicine.SUBSTANCE: there is conducted addition of biologically active substances (BAS) to a perfluorocarbon (PFC) emulsion containing at least: perfluordecahydronaphthalene and/or perfluormethylcyclohexylpiperidine and/or perfluortributylamine and/or perfluoroctylbromide stabilised by a proxanol solution and/or phospholipids. The PFC emulsion with the BAS is added to stem cells (SC) for co-cultivation. After cultivation, the SC are introduced to a subject requiring the BAS introduction.EFFECT: invention allows providing targeted transport of the BAS into the body.16 cl, 7 dwg, 1 tbl, 3 ex

Bioadhesive carrier with delayed release for mucous membranes, intended for delivery of active components // 2420267
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to bioadhesive carrier for mucous membranes with delayed release of active component. Carrier contains primary granules, which include active component, 1-75 wt % of diluting agent 1-10 wt % of alkyl sulfate of alkaline metal and 0.5-5 wt % of binding substance, as well as 5-80 wt % of bioadhesive polymer, selected from group including natural polymers, said natural polymers represent polysaccharides, natural proteins of animal or vegetable origin, or synthetic polymers and 5-80 wt % of polymer, ensuring delayed release of active component, carrier does not contain lactose and corn starch. Said carrier ensures delivery of active component during long period, constituting more than 20 hours.EFFECT: invention relates to method of obtaining bioadhesive carrier and to its application for treatment of mucous membrane diseases.33 cl, 7 dwg, 2 tbl, 13 ex
Preservative composition for ophthalmic application // 2413534
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine, in particular to ophthalmology. A liquid drug for ophthalmic application contains a preservative composition for ophthalmic application containing chlorite and at least one preservative chosen from a group: 1) creatinine, 2) geraniol, 3) glucose, 4) tocopherol acetate, 5) oxyquinoline sulphate, 6) sugar alcohol and 7) polyoxyethylene ester of sorbite and fatty acid.EFFECT: invention prevents formation of chlorine dioxide in the liquid drug for ophthalmic application, containing chlorite and exhibits a prolonged preservative effect.6 cl, 5 tbl, 4 ex

Capsules for inhalers // 2412722
FIELD: medicine.SUBSTANCE: in capsule, in accordance with the invention, at least, one hollow space is surrounded by wall. At least, part of wall includes polymer mixture, which contains, at least, one adsorbent. Polymer mixture contains, at least, thermoplastic material, preferably polyolefin, more preferably, polyethylene or polypropylene. Adsorbent is selected from group, consisting of silica gels, zeolites, alumosilicates, molecular sieves, active coal, oxides of alkali-earth metals, calcium sulfate. Capsule is intended for packing compositions for inhalation.EFFECT: invention allows to prolong stability of medication compositions.28 cl, 8 dwg

Drug container and method of its manufacturing // 2406536
FIELD: medicine.SUBSTANCE: invention relates to nanobiotechnology in field of medicine. Nanodiamond powder with particle size not more than 10 nm is placed in press-form and formed at pressure 50-300 MPa. Formed semi-product is thermally processed in medium of gaseous hydrocarbons during time which ensures obtaining porosity 40-75 vol. %. Inorganic base, made from biocompatible carbon composite material, representing nanodiamond particles, bound by graphite-like carbon, is obtained. Pores of obtained base are filled with medication by soaking with medication solution or medication adsorption from its solution.EFFECT: invention allows to increase drug container efficiency, extend classes of obtained medications in combination with simplification of technology of its manufacturing.2 cl, 1 dwg, 3 ex

Pharmaceutical composition // 2394573
FIELD: medicine.SUBSTANCE: invention relates to veterinary. Pharmaceutical composition for treatment of ear infection in animals contains orbifloxacin or one of its pharmaceutically acceptable salts, efficient amount of antifungal pharmaceutically acceptable triazole compound, mometasone furoate monohydrate and at least one pharmaceutically acceptable carrier, where said composition represents suspension. Pharmaceutical composition for treatment of infection in animals contains orbifloxacin or one of its pharmaceutically acceptable salts, efficient amount of antifungal compound, represented by chemical structural formula I: mometasone furoate monohydrate and at least one pharmaceutically acceptable carrier, where said composition represents suspension. Pharmaceutical composition for treatment of ear infection in animals contains quinol antibiotic, efficient amount of antifungal pharmaceutically acceptable triazole compound, mometasone or one of its pharmaceutically acceptable salts, and at least one pharmaceutically acceptable carrier, where said composition represents suspension.EFFECT: said pharmaceutical compositions ensure increase of animal treatment efficiency and reduction of irritating action in place of introduction.17 cl, 1 ex, 1 dwg, 1 tbl

Granules containing nsaid and sugar alcohol prepared by melt extrusion // 2389480
FIELD: medicine, pharmaceutics.SUBSTANCE: pharmaceutical composition contains a granulated component including multiple hardened melt granules of sugar alcohol containing salt of nonsteroidal anti-inflammatory drug (NSAID salt). The pharmaceutical composition is used for managing pain and/or inflammation and/or febrilily in coughing, cold, influenza, migraine, headache, rheumatic pain, arthritis pain, muscular pain and/or neuralgia.EFFECT: according to the invention, the pharmaceutical composition contains minimum of tableting excipients, has improved fluidity, is less sticky, than NSAID salt itself and exhibits preferable tableting, disintegrating and dissolution properties.39 cl, 3 dwg, 3 tbl, 29 ex

Granules containing paracetamol, nsaid and sugar alcohol prepared by melt extrusion // 2389478
FIELD: medicine.SUBSTANCE: pharmaceutical composition contains a granulated component including multiple hardened melt granules of sugar alcohol containing included salt of nonsteroidal anti-inflammatory drug (NSAID salt) and paracetamol. The mass ratio of NSAID salt to paracetamol is 1:5 to 3:1. The pharmaceutical composition is used for pain and/or inflammation and/or fever management in coughing, cold, influenza, migraine, headache, rheumatic pain, articular pain, muscular pain and/or neuralgia.EFFECT: according to the invention, the pharmaceutical composition contains minimum of tableting excipients, has improved fluidity and does not tend to adhere to stamps of a tableting machine.38 cl, 3 dwg, 4 tbl, 21 ex

ethod for preparing aqueous pharmaceutical composition including hydroxymethylpropylmethylcellulose, and pharmaceutical compositions prepared by said method // 2389476
FIELD: medicine, pharmaceutics.SUBSTANCE: aqueous pharmaceutical composition containing: a) 0.005-10 wt % of one or more water-soluble pharmaceutically active components or their pharmaceutically acceptable salts; b) 0.01 to 10 wt % of hydroxypropylmethylcellulose with viscosity 2500 to 5500 sP (mPa*s); and c) a buffer for maintaining a pH level of a pharmaceutical composition within 5 to 7, can be prepared by a method which involves: i) dissolution of said components in water to form an aqueous solution, and ii) filtering of the aqueous solution prepared at the stage i), through a filter of pore size ≥ 1 micron and ≤10 micron.EFFECT: compositions prepared by said method are able to exhibit improved mucoadhesive ability and stability.13 cl, 2 tbl, 8 ex
Pharmaceutical composition for correction of psychosomatic manifestations // 2384336
FIELD: medicine.SUBSTANCE: pharmaceutical composition contains alimemazine as an active component, and target adjuvants: lactose, potato starch, microcrystalline cellulose, kollidon, magnesium stearate in the following ratio. The composition is made in the form of coated tablets with the coating containing polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, acceptable dying agents.EFFECT: pharmaceutical composition extends range of medical products, meets all of the standard requirements and has shelf-life of 2 years.5 cl, 2 ex

Pharmaceutical compounds with improved pharmaceutical properties containing flavouring substances // 2377018
FIELD: medicine.SUBSTANCE: present invention concerns medical products, particularly a tableted solid veterinary-medical compound containing a pharmaceutical active raw material (particularly enrofloxacin, pradofloxacin) 0.001 to 90 wt %, a flavouring and/or aromatic substance representing Bayopal and Artificial Beef Flavor, in amount 5% to 15% in terms of total mass of ready compound and at least 1.5 wt %, and no more than 15 wt % of fine-grained silicon dioxide in terms of total mass of ready compound, and one or more adjuvants.EFFECT: such qualitative and quantitative composition of tablets provides comprehensible flavouring properties thereof with preserving pharmaceutical properties (particularly solidity).3 cl, 10 dwg, 9 tbl, 5 ex
ethod of making nanosised system for delivering medicinal agents based on silicon dioxide // 2372890
FIELD: chemistry.SUBSTANCE: invention relates to a method of making a nanosised system for delivering met-enkephalin on a hydrosol of SiO2 nanoparticles, involving mixing distilled water, hydrochloric acid and tetraethoxysilane, addition of a prepared NaOH solution, evaporation and filtration, obtaining a SiO2 hydrosol, ultrasonic treatment of the obtained SiO2 hydrosol, addition of met-enkephalin and surfactant solution in amount ranging from 0.5 to 2% of total volume of the obtained system.EFFECT: system of delivering met-enkephalin is capable of penetrating the hematoencephalic barrier and deliver medicinal agents to brain cells.2 ex, 2 tbl

Tablet containing fluvastatin and sodium carboxymethylcellulose of calcium // 2361582
FIELD: medicine.SUBSTANCE: invention concerns a tablet containing fluvastatin with sodium carboxymethylcellulose of calcium in the form of raising agent. The fluvastatin tablet is characterised by time of disintegration from 10 to 30 minutes and good bioavailability equivalent to bioavailability of serially produced capsules, containing fluvastatin. Manufacturing of tablets does peroral application of fluvastatin economically more favourable and more convenient for patients.EFFECT: rising of profitability and convenience of peroral fluvastatin application to patients.12 cl, 7 dwg, 6 tbl, 2 ex

Tuberculous agent as solution for injection // 2358742
FIELD: medicine.SUBSTANCE: pharmaceutical agent is developed as a solution for injection containing 1-isonicotyl-2-glucosylhydrazone dehydrate (isoglucosyl) concentrated 0.1% to 10% as an active principle, and pharmaceutically acceptable carrier - water for injection.EFFECT: high antituberculous activity and low toxicity.4 dwg
 
2551407.
Up!